Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.

ABSTRACT: Pancreatic ductal adenocarcinoma is the seventh leading cause of cancer death worldwide with an estimated 432 242 deaths occurring in 2018. This estimate, in conjunction with the findings that pancreatic ductal adenocarcinoma incidence is rising and that pancreatic ductal adenocarcinoma has the highest case-fatality rate of any solid tumour, highlights the urgency for designing novel therapeutic strategies to combat this deadly disease. Through the efforts of the global research community, our knowledge of the factors that lead to the development of pancreatic ductal adenocarcinoma, its progression, and the interplay between tumour cells and their surrounding microenvironment have improved substantially. Although these scientific advances have not yet translated into targeted or immunother

SUBMITTER: Christenson ES 

PROVIDER: S-EPMC8011058 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature